Acute myeloid leukemia

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Retrieved on: 
Thursday, December 14, 2023

The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.

Key Points: 
  • The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.
  • ET featuring presentations by members of Sutro’s senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
  • To access the live audio webcast on Thursday, January 4, at 1:30 p.m. PT / 4:30 p.m.
  • ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
    An archived replay of the webcast will be available on the Company’s website following the live presentation.

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

Retrieved on: 
Thursday, December 14, 2023

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
  • “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
  • The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
  • “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 14, 2023

The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.

Key Points: 
  • The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.
  • The approved treatment cycle is two doses per week over four weeks for a total of eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first patients have been enrolled in the 60 mg dose cohort in its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

Key Points: 
  • A total of nine patients have been enrolled at the 45 mg safety dose level.
  • Eight patients remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.
  • The first enrolled patient achieved a complete response and is currently in the seventh month of treatment and the second enrolled patient is in the sixth month of treatment.
  • In the 60 mg dose cohort, patients will be randomized to one of two groups, 60 mg flat (fixed) dose once per week and 30 mg fixed dose two times per week.

NextCure Provides Year-End Clinical Pipeline Updates

Retrieved on: 
Thursday, December 14, 2023

BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.

Key Points: 
  • BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.
  • Given evidence of clinical activity to date, additional patients are being added to the 100 mg cohort of patients with microsatellite stable / microsatellite instable-low immune checkpoint inhibitor naïve colorectal cancer without active liver metastasis.
  • Clinical data, including results from additional patients, are expected in the first half of 2024.
  • Data defining the mechanism of action were published in Journal of Clinical Investigation in November.

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

Retrieved on: 
Wednesday, December 13, 2023

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time.

Key Points: 
  • NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time.
  • Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company’s achievements in 2023 and provide an outlook for 2024.
  • Dr. Stergiou will be joined by two key opinion leaders and principal investigators who will discuss the Phase 3 registrational REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia and the clinical program for SLS009, the Company’s CDK9 inhibitor:
    Dr. Panagiotis Tsirigotis, Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
    Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas
    To access the webinar, please use the following information:

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Retrieved on: 
Monday, December 11, 2023

Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Please use this link to participate in the live call; a listen-only version of the webcast is available here .
  • “Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need.
  • In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics.

NMDP/Be The Match® PTCy Research Levels the Field between Matched and Mismatched Hematopoietic Cell Transplantation

Retrieved on: 
Monday, December 11, 2023

The study shows the practice-changing potential of using mismatched unrelated donors (MMUD) to expand access to all patients regardless of ancestry.

Key Points: 
  • The study shows the practice-changing potential of using mismatched unrelated donors (MMUD) to expand access to all patients regardless of ancestry.
  • “However, PTCy has transformed the allogeneic HCT landscape, enabling successful use of mismatched related and unrelated donor HCT by transcending the HLA barrier.
  • This research not only confirms the efficacy of PTCy, but also alludes to its promise to provide allogeneic HCT to essentially all patients irrespective of their ancestry.
  • The study was designed to determine if PTCy can eliminate disparities in GRFS and OS between matched (8/8) and single mismatched (7/8) URD compared to haploidentical (half matched)-related donors.

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 11, 2023

“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.

Key Points: 
  • “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
  • All data presented from this trial is as of the data cut-off date.
  • 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023

Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.

Key Points: 
  • Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
  • The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
  • KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
  • “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.